SAN DIEGO—OncoSec Medical Inc. a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, and OncoSec’s ImmunoPulse (intratumoral IL-12) in metastatic melanoma
MRV Research
Microcost techniques help estimate specialized services cost for patients at high risk for melanoma
Use of microcosting techniques helped determine an accurate cost estimate for the provision of specialized surveillance and treatment of patients at high risk for melanoma, according to study findings.
BMS, Five Prime Plan Cancer Combo Trial, in $30M+ Expansion of Alliance
Bristol-Myers Squibb (BMS) and Five Prime Therapeutics said today they will launch a Phase Ia/Ib study to assess the safety, tolerability, and preliminary efficacy of combining the pharma giant’s Opdivo (nivolumab) with the biotech’s monoclonal antibody FPA008 in six types of tumors
TNF-alpha inhibitors associated with uveal melanoma
According to new findings reported in the journal Mayo Clinic Proceedings, researchers warn that there may be a correlation between tumor necrosis factor (TNF)-alpha inhibitors and the development of uveal melanoma.